DePuy Synthes Launches VELYS™ Hip Navigation with AI to Support Intraoperative Consistency and Efficiency in Total Hip Arthroplasty

RAYNHAM, Mass., June 9, 2026- DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced the U.S. commercial availability of VELYS™ Hip Navigation with AI Assistance. This next-generation software solution, powered by the VELYS™ Hub, includes new artificial intelligence capabilities to advance the standard of care in total hip arthroplasty (THA) by automating image interpretation, consistently identifying landmarks, and increasing procedural efficiencies.^2†

THA demand continues to rise, with approximately 850,000 procedures projected annually in the U.S. by 2030, representing a 129% increase from 2014.³ Despite the overall success of these procedures, as volumes grow and operating room demands intensify, there is increasing need for technologies that support efficient workflows, consistent intraoperative execution, and real-time decision-making.⁴

VELYS™ Hip Navigation with AI Assistance helps address this need by automating image interpretation and landmark identification to deliver real-time, patient-specific insights on leg length, offset, and cup position.^2† The AI model is trained on geographically diverse, deidentified clinical datasets⁵ and operates within a human-in-the-loop design, ensuring surgeons retain full control over final anatomical landmark placement.⁵ By reducing reliance on manual interpretation and integrating seamlessly into existing surgical workflows, VELYS™ Hip Navigation with AI Assistance enables quicker access to relevant data, enhancing decision making and efficiency in the operating room.^2,6‡

"The introduction of VELYS™ Hip Navigation with AI Assistance advances our commitment to delivering data-driven technologies that support surgeon decision-making and procedural consistency," said Sharrolyn Josse, Global President, Joint Reconstruction, DePuy Synthes. "This solution is designed to streamline workflows and reduce complexity by providing real-time, patient-specific insights. It is not simply an update to VELYS™ Hip Navigation; it is the next generation of the platform, built to keep control in the surgeon's hands."

VELYS™ Hip Navigation with AI Assistance is available on the VELYS™ Hub, an advanced hardware optimized to unlock the full potential of AI-driven clinical care.^7-11 The system features a 32-inch 4K high-resolution monitor^{9, 12-13} with a 79% larger viewing area than legacy hardware,^7-11,12** an integrated image-capture card for C-arm connectivity,^{9-11, 13, 15} and GPU optimized architecture¹⁶ to enable real-time intraoperative insights.^7-11,16

"In total hip arthroplasty, achieving consistent implant positioning and restoring patient specific biomechanics are critical to long term success," said Christopher N. Johnson, D.O., Ortho Northeast.* "Technologies such as VELYS™ Hip Navigation with AI Assistance have the potential to help reduce variability, improve intraoperative efficiency and workflow, and support surgeon decision making and control in the operating room."

Surgeons interested in learning more or inquiring about the availability of VELYS™ Hip Navigation are encouraged to visit the product page.

DePuy Synthes provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement to the millions of patients we serve. Our solutions-including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery, and sports medicine-alongside the VELYS™ Digital Surgery portfolio, are designed to support improved patient care and deliver clinical and economic value to healthcare systems worldwide. Building on a legacy of product innovation and industry firsts, we continue to shape the orthopaedic landscape through advancements in medical technologies and digital surgery across the continuum of care to Keep People Moving today and tomorrow.

About DePuy Synthes
DePuy Synthes provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement to the millions of patients we serve. Our solutions-including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery, and sports medicine-alongside the VELYS™ Digital Surgery portfolio, are designed to support improved patient care and deliver clinical and economic value to healthcare systems worldwide. Building on a legacy of product innovation and industry firsts, we continue to shape the orthopaedic landscape through advancements in medical technologies and digital surgery across the continuum of care to Keep People Moving today and tomorrow.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions atjnj.com. Follow us at @JNJMedTech and on LinkedIn. DePuy Synthes Products, Inc. is a Johnson & Johnson company.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding VELYS Hip Navigation with AI Assistance. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Important Information: Prior to use, refer to the instructions for use supplied with the device(s) or indications, contraindications, warnings and precautions.

Important Information: Prior to use, refer to the instructions for use supplied with the device(s) or indications, contraindications, warnings and precautions.

© DePuy Synthes and its affiliates 2026. All rights reserved. US_ORT_DGSR_416413

^† Pre-clinical test data/results may not necessarily be indicative of human clinical performance (or outcomes)
^‡ Pre-clinical test data/results may not necessarily be indicative of human clinical performance (or outcomes) & compared to manual workflow
** When compared to the legacy VHN 24" monitor
* Christopher N. Johnson, D.O., serves as a consultant for DePuy Synthes but was not compensated for this announcement

Footnotes
¹ Hudson A, Marshall B, Leestma S, Diaz R. THA Software System Comparing Outputs from AI to Human Operators. Poster presented at: ORS 2026 Annual Meeting; 2026; Charlotte, NC USA.
² Johnson & Johnson and its affiliates. Software Design Validation Report VELYS Hip Navigation AI. August 2025
³ Singh JA, Yu S, Chen L, Cleveland JD. Rates of Total Joint Replacement in the United States: Future Projections to 2020-
2040 Using the National Inpatient Sample. J Rheumatol. 2019;46(9):1134-1140. doi:10.3899/jrheum.170990
⁴ Andriollo L, Picchi A, Iademarco G, Fidanza A, Perticarini L, Rossi SMP, Logroscino G, Benazzo F. The Role of Artificial Intelligence and Emerging Technologies in Advancing Total Hip Arthroplasty. J Pers Med. 2025 Jan 9;15(1):21. doi:
10.3390/jpm15010021. PMID: 39852213; PMCID: PMC11767033.
⁵ Johnson & Johnson and its affiliates. VELYS Hip Navigation AI User Guide. 2025
⁶ Goodell P, Ellis S, Kokobun B, Wilson H, Kollmorgen RC.Computer navigation vs. conventional overlay methods in direct anterior total hip arthroplasty: A single surgeon experience. Cureus. October 2022. doi:10.7759/cureus.29907
⁷ Johnson & Johnson and its affiliates. Vector Requirements and Traceability Matrix. October 2025. Windchill # 502129480 Rev C.
⁸ Johnson & Johnson and its affiliates. VELYS Computer Drawing. October 2025. Windchill # 502198827 Rev B.
⁹ Johnson & Johnson and its affiliates. VELYS Computer Drawing Review. October 2025. Windchill # 502331420 Rev A.
¹⁰ Johnson & Johnson and its affiliates. VELYS Hub Design Validation Report End to End Systems Integration. October 2025. Windchill # 502336337 Rev A.
¹¹ Johnson & Johnson and its affiliates. VELYS Hub Claims Memo. November 2025. Windchill #502489090 Rev A.
¹² Johnson & Johnson and its affiliates. VELYS Touchscreen 32. October 2025. Windchill # #811111347 Rev C
¹³ Johnson & Johnson and its affiliates. VELYS Cybermed All in One PC. October 2025. Windchill #103852740 Rev A.
¹⁴ Koy T. Screen Size Calculator - Calculator Hub. Calculator Hub. Published March 5, 2024. Accessed October 31, 2025. https://calculatorhub.app/screen-size-calculator/
¹⁵ Johnson & Johnson and its affiliates. VELYS Hub Design Verification Report for C-Arm Connectivity. October 2025.
Windchill #502306443 Rev B.
¹⁶ Johnson & Johnson and its affiliates. VHN Al on VELYS Hub Claim Support Memo. Hardware Minimum Specification
Verification. November 2025.

Media Contact:
Lindsey Diaz-MacInnis
[email protected]